Stock VRP VERONA PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Verona Pharma plc Stock London S.E.

Equities

VRP

GB00BYW2KH80

Biotechnology & Medical Research

Delayed London S.E.
Other stock markets
 12:35:15 2020-10-29 pm EDT 		5-day change 1st Jan Change
55 GBX +5.77% Intraday chart for Verona Pharma plc +4.76% -11.29%
Jul. 16 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
Jul. 15 European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT

Financials

Sales 2024 * 4.75M 6.19M Sales 2025 * 66.09M 86.11M Capitalization 1.39B 1.82B
Net income 2024 * -104M -136M Net income 2025 * -84M -109M EV / Sales 2024 * 293 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 21.1 x
P/E ratio 2024 *
-24.2 x
P/E ratio 2025 *
-39.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.42%
More Fundamentals * Assessed data

Chart Verona Pharma plc

Dynamic Chart

Latest news about Verona Pharma plc

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Truist Securities Raises Price Target on Verona Pharma to $38 From $32, Maintains Buy Rating MT
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease MT
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month RE
Transcript : Verona Pharma plc - Special Call
HC Wainwright Adjusts Price Target on Verona Pharma to $36 From $32, Maintains Buy Rating MT
Verona Pharma Gets FDA Nod for Pulmonary Disease Treatment; Shares Jump Premarket MT
The same old winners Our Logo
Verona Pharma Gets US FDA Approval for Ohtuvayre in Chronic Obstructive Pulmonary Disease MT
FDA approves Verona Pharma's therapy for 'smoker's lungs' RE
Verona Pharma Announces US FDA Approval of Ohtuvayre (Ensifentrine) CI
More news

Latest transcript on Verona Pharma plc

Logo Verona Pharma plc
Verona Pharma plc - Special Call
More transcripts

Analyst Recommendations on Verona Pharma plc

Truist Securities Raises Price Target on Verona Pharma to $38 From $32, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Verona Pharma to $36 From $32, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating MT
Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating MT
More recommendations

Press releases Verona Pharma plc

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre, First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years AQ
Verona Pharma Announces US FDA Approval of Ohtuvayre AQ
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) AQ
Verona Pharma : VRNA Presentation May 2024 PU
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS AQ
More press releases

News in other languages on Verona Pharma plc

EEUU - Valores a vigilar en Wall Street (actualizado)
More news

Managers and Directors - Verona Pharma plc

Managers TitleAgeSince
David Zaccardelli CEO
 Chief Executive Officer 59 20-01-31
Mark Hahn DFI
 Director of Finance/CFO 61 20-02-29
Kavita Aggarwal CTO
 Chief Tech/Sci/R&D Officer - 22-12-31
Members of the board TitleAgeSince
Mahendra Shah BRD
 Director/Board Member 79 16-06-16
Vikas Sinha BRD
 Director/Board Member 60 16-09-11
David Ebsworth CHM
 Chairman 69 14-11-30
More insiders

Company Profile

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Sector
Biotechnology & Medical Research
Calendar
2024-08-05 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
22.26 USD
Average target price
36.17 USD
Spread / Average Target
+62.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.17% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.67% 118B
ARGENX SE Stock argenx SE
+23.55% 27.87B
BIONTECH SE Stock BioNTech SE
-17.74% 20.95B
GENMAB A/S Stock Genmab A/S
-16.15% 16.92B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.21% 16.18B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.91% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 14.79B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.50% 14.08B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRNA Stock
  4. VRP Stock